(Reuters) - MADRID, July 20 - Shares in Spanish drug company Zeltia soared on Friday after its cancer treatment Yondelis was recommended for approval in Europe, its first medicine to make its way to the market. Zeltia shares were 19.4 percent higher at 9.79 euros at 0800 GMT after the European Medicines Agency late on Thursday recommended Yondelis be approved by the European Commission, a process which usually takes a couple of months.
The company said Yondelis should be available to treat soft tissue sarcomas by the end of the year.
Read more at Reuters.com Government Filings News
The company said Yondelis should be available to treat soft tissue sarcomas by the end of the year.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment